US EditionL.A. Jury Awards $40M in Ovarian Cancer Talc Trial; J&J Vows Appeal
8 Articles
8 Articles
In October, another California jury ordered J&J to pay $966 million to the family of a woman who died of mesothelioma.
L.A. jury awards $40M in ovarian cancer talc trial; J&J vows appeal
LOS ANGELES - A Los Angeles County jury has ordered pharmaceutical and personal care product maker Johnson & Johnson to pay a combined $40 million to two women who claim they contracted ovarian cancer from trace amounts of asbestos allegedly…
Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook
CAs of Wednesday, December 17, 2025, Johnson & Johnson (NYSE: JNJ) is back in focus for investors looking for a “defensive” large-cap healthcare stock—while also weighing two forces that can move JNJ shares quickly: drug pipeline catalysts and talc litigation headlines. JNJ shares are trading around $210 today, after a volatile stretch that included a sharp pullback on Tuesday, December 16, and renewed analyst attention mid-week. StockAnalysis J…
Telemundo Fresno
Telemundo 20A Los Angeles jury awarded $40 million to two women who claimed that Johnson & Johnson’s talcum made them ovarian cancer. The company of personal care products indicated that it will appeal the verdict on liability and compensatory damages. Friday’s ruling is the most recent event of a protracted legal battle over allegations that Johnson’s baby powder talcum powder and shower to shower body powder were related to ovarian cancer and mesothelioma…
A Los Angeles jury awarded $40 million to two women who claimed that Johnson & Johnson’s talcum made them ovarian cancer. The company of personal care products indicated that it will appeal the verdict on liability and compensatory damages. Friday’s ruling is the most recent event of a protracted legal battle over allegations that Johnson’s baby powder talcum powder and shower to shower body powder were related to ovarian cancer and mesothelioma…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
